Decision: Favourable

Study Title:

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated

  • NREC Code:

    22-NREC-CT-026

  • Decision:

    Favourable

  • Meeting Date:

    23/02/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Anne Fortune

  • PI Institution:

    MMUH

  • Sponsor:

    Loxo Oncology Inc.

Scroll to Top
Skip to content